4.7902.64% ( -0.130 )
Closed: Oct 23, 16:00:00 (EDT)Q2 FY2026 EarningsQ2 FY26 results missed consensus on the top-line, with revenue of $320.1M coming in 7.3% below the $345.2M expected. Adjusted EPS of $0.20 was in-line with consensus, though GAAP figures were heavily impacted by a $78.9M non-cash impairment and a significant valuation allowance on deferred tax assets, resulting in a GAAP loss of $5.14 per share. Revenue declined 17.1% YoY, driven by broad-based weakness across all Nu Skin reporting segments, particularly in the Americas (-18.1%) and South Korea (-24.8%). Full-year FY26 revenue guidance was lowered to $1.28B–$1.35B, significantly trailing the implied prior market expectations.
Financial report interval: 2026.03.30 - 2026.06.30
Overview: Nu Skin(NUS) the Revenue is 320.11 M (-17.1%), Miss estimate;the EBIT is -59.32 M (--%), Miss estimate;the EPS is -5.14 (-1295%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueMiss expectations
0.32B17.10%
0.35B10.60%
-0.03B6.50%
EBITMiss expectations
-0.06B--
0.02B--
-0.08B--%
EPSMiss expectations
-5.141295.35%
0.253.49%
-5.34001,241.86%
Upcoming earnings report - Q3 FY2026
Available dateNov 5, 2026
Estimate Revenue$328.7 M
Estimate EBIT$13.2 M
Estimate EPS$0.14
Revenue
ActualEstimateUnit: USD
Quarterly
EBIT
ActualEstimateUnit: USD
Quarterly
Net income
ActualEstimateUnit: USD
Quarterly
EPS
ActualEstimateUnit: USD
Quarterly
